1. GScale AI data center entry - SETL completed the 33.55% acquisition of GScale Energy on July 30, 2026, with a ₹190 Cr Phase I investment (₹125 Cr cash + ₹65 Cr share swap) toward a \~₹500 Cr self-funded programme. GScale targets \~₹250 Cr revenue in FY27 from its 4-lakh-sq-ft factory live November 2026, at 23-25% EBITDA margins, with LOAs from leading datacenter clients in final closure.
2. Scigenics and C2C acquisitions - Both acquisitions completed and integrated during FY26, contributing \~₹44 Cr combined revenue, with FY27 targets of \~₹60 Cr each. C2C adds concept-to-commissioning EPC capability with a ₹46-47 Cr order book, while Scigenics opens the bioprocess and fermentation market, together adding \~₹100 Cr incremental FY27 revenue.
3. Greenfield campus expansion - Construction started on a 36-acre facility with ₹130 Cr capex split across FY27-FY28, first phase (50%) operational from April 1, 2027. The new facility adds \~₹2,000 Cr revenue capacity on top of existing facilities' \~₹2,000 Cr potential, with 100-ton crane and 100mm fabrication capability opening heavy engineering and oil & gas orders.
4. Conductivity glass reactors - Multiple units manufactured, supplied and validated in regulated pharma markets, with official India and global launch from April 2027 and international partner IPP expressing strong interest in global distribution. This safety-critical, static-discharging technology is unique to GL Hakko, with orders from Hetero and Sun Pharma already supplied, and an order from Laurus Labs to be supplied.
5. Middle East distribution agreement - SETL signed a target-based conditional distribution agreement with API Pharma (UAE) on March 5, 2026, covering exports across pharma, biopharma and food & beverage for an initial three-year period extendable to ten years. This follows export revenue doubling in FY26, with management targeting 15-20% export contribution within two years.